--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-176725" form_type: "8-K" ticker: "IKT" cik: "0001750149" company_name: "Inhibikase Therapeutics, Inc." filed_at: "2023-06-28T23:59:59+00:00" generated_at: "2026-06-13T15:36:57.733360+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.5 confidence: "high" source: SEC EDGAR --- # Inhibikase Therapeutics shareholders reject share increase, approve reverse split at 2023 annual meeting ## Summary - Dennis Berman and Gisele Dion elected as Class III directors with 16.3M and 16.7M votes for, respectively. - Proposal to increase authorized shares from 100M to 200M failed (20.6M for, 2.2M against; not enough votes). - Approved reverse stock split authorization (1-for-5 to 1-for-20) with 21.9M votes. - Proposal to eliminate supermajority vote requirement for charter amendments failed (15.5M for, 6.1M broker non-votes). - Ratification of CohnReznick as auditor passed with 22.8M votes for. ## SEC filing metadata - accession: 0001193125-23-176725 - form_type: 8-K - ticker: IKT - cik: 0001750149 - company_name: Inhibikase Therapeutics, Inc. - filed_at: 2023-06-28T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.5 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312523176725/0001193125-23-176725-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312523176725/d518755d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-176725 - JSON: https://secwatch.observer/filing/0001193125-23-176725.json - Plain text: https://secwatch.observer/filing/0001193125-23-176725.txt ## Key facts - Shareholder Votes Inhibikase Therapeutics, Inc. shareholders rejected To approve an amendment to Article XII of the Company’s Amended and Restated Certificate of Incorporation to eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof at the 2023-06-23 meeting. - Proposal: charter amendment - Outcome: failed - Meeting: 2023-06-23 source text: Proposal Five : To approve an amendment to Article XII of the Company’s Amended and Restated Certificate of Incorporation to eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof. Total Votes For 15,474,907 Against 1,373,915 Abstain 180,767 Broker Non-Votes 6,084,269 evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312523176725/0001193125-23-176725-index.htm - Shareholder Votes Inhibikase Therapeutics, Inc. shareholders approved To grant discretionary authority to the board of directors to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the common stock of the Company within a range of 1-for-5 to 1-for-20, if needed to meet the minimum bid requirement under The Nasdaq at the 2023-06-23 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2023-06-23 source text: Proposal Four : To grant discretionary authority to the board of directors to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the common stock of the Company within a range of 1-for-5 to 1-for-20, if needed to meet the minimum bid requirement under The Nasdaq Capital Market listing rules with the exact ratio, if any, to be determined by the board of directors. Total Votes For 21,949,971 Against 1,156,412 Abstain 7,473 Broker Non-Votes 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312523176725/0001193125-23-176725-index.htm - Shareholder Votes Inhibikase Therapeutics, Inc. shareholders approved To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-23 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-23 source text: Proposal Three : To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Total Votes For 22,817,751 Against 36,084 Abstain 260,023 Broker Non-Votes 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312523176725/0001193125-23-176725-index.htm - Shareholder Votes Inhibikase Therapeutics, Inc. shareholders rejected To grant discretionary authority to the board of directors to amend the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares at the 2023-06-23 meeting. - Proposal: charter amendment - Outcome: failed - Meeting: 2023-06-23 source text: Proposal Two : To grant discretionary authority to the board of directors to amend the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares. Total Votes For 20,642,707 Against 2,190,425 Abstain 280,725 Broker Non-Votes 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312523176725/0001193125-23-176725-index.htm - Shareholder Votes Inhibikase Therapeutics, Inc. shareholders approved Election of Dennis Berman and Gisele Dion as Class III directors at the 2023-06-23 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-23 source text: Proposal One : To elect two directors to the board of directors of the Company to serve as Class III directors, to serve until the Company’s 2026 annual meeting of stockholders, or until in each case their respective successor is duly elected and qualified. The nominees for election were Dennis Berman and Gisele Dion. The following nominees were elected by the votes indicated to serve as Class III directors, to serve until the Company’s 2026 annual meeting of stockholders, or until in each case their respective successor is duly elected and qualified: Name Total Votes for Director Total Votes Withheld from Director Total Broker Non-Votes Dennis Berman 16,347,928 681,661 6,084,269 Gisele Dion 16,729,483 300,106 6,084,269 evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312523176725/0001193125-23-176725-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.